EditCo Bio, Inc. Unveils Novel Knockout CD4+ T-cell Pools to Transform Cancer and Autoimmune Research
Retrieved on:
Thursday, April 18, 2024
Health Technology, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Oncology, General Health, Genetics, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, Cancer, CRISPR, Genetic engineering, Immunotherapy, Gene editing, Cell, Cryopreservation, CSO, Cell engineering, Knockout, TCR, IL2, TNFA
EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools .
Key Points:
- EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools .
- T-cells, pivotal in the immune response, hold immense promise for elucidating the pathways of various diseases, including cancer and autoimmune conditions.
- The introduction of Knockout CD4+ T-cell Pools is a strategic extension of EditCo Bio’s comprehensive Engineered Cell portfolio.
- For more information regarding EditCo Bio’s CD4+ T-cell Pools, visit www.EditCo.bio/contact .